10 stories found
Several companies across various sectors are either releasing their first-quarter 2026 earnings reports or providing previews of their financial performance. These reports offer insights into the companies' recent business operations and financial health.
Chardan, a financial firm, has maintained its "Buy" rating on Iovance Biotherapeutics (IOVA) stock.
Iovance Biotherapeutics Inc. is gaining momentum following the release of new trial data.
Several companies, including Crexendo, EQT, and Ally Financial, have announced or reported their financial results for the first quarter of 2026. These reports include details on earnings per share and revenue performance.
Iovance Biotherapeutics (IOVA) reported a 61% annual revenue growth, primarily attributed to the success of its drug Amtagvi.
Jefferies has drawn attention to Iovance Biotherapeutics Inc. and its Amtagvi drug, indicating potential interest or developments in the biopharmaceutical sector.
Hedge funds are identifying Iovance Biotherapeutics Inc. (IOVA) and AstraZeneca PLC (AZN) as leading immunotherapy stocks to buy.